12:00 AM
 | 
May 04, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Apo2L/TRAIL: Phase Ib start

This quarter, the partners plan to begin an open-label, dose-escalation, U.S. Phase Ib trial to evaluate IV dulanermin in combination with FOLFOX chemotherapy and Avastin bevacizumab in 23 previously-untreated patients....

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >